Seletracetam (Ucb 44212) lithium bromide is a SV2A modulator, intended for epilepsy research. It is an analog of Levetiracetam, an antiepileptic agent.

Seletracetam displays one-log-unit higher affinity (pKi=7.1) than Levetiracetam (6.1) to the LEV-binding site[2]. Seletracetam lithium bromide inhibits high-voltage-activated Ca 2+ currents and intracellular Ca 2+ increase in rat cortical neurons in vitro[2]. Seletracetam (1-10 μM) lithium bromide reduces both the amplitude and repetitive firing of population spikes induced by a high K + /low Ca 2+ concentration fluid (HKLCF) in rat hippocampal slices[3].

Seletracetam (intraperitoneal injection) lithium bromide displays potent protection against secondary generalised motor seizures in fully corneally-kindled mice (ED 50 0.31 mg/kg). In audiogenic seizure susceptible mice, Seletracetam (i.p) protects against clonic convulsion expression with an ED 50 of 0.17 mg/kg[3]. Seletracetam (0.0074 mg/kg to 74 mg/kg; intraperitoneal injection) lithium bromide increases the generalized seizure threshold current and decreases the duration of the after-discharge and the seizure severity observed at the after-discharge threshold current, and generally has a much more potent effect than previously observed for Levetiracetam[3]. Animal Model: Female Wistar rats (200-220 g) (Amygdala-kindled rats)[3]Dosage: 0.0074,7.4, 74 mg/kg Administration: Intraperitoneal injection; 60 min before seizure threshold determination Result: Markedly increased the generalized seizure threshold at all doses tested, with increases of 190% (0.0074 mg/kg), 302% (0.074 mg/kg), 429% (0.74 mg/kg), 433% (7.4 mg/kg) and 679% (74 mg/kg).